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ABSTRACT 
Fast dissolving dosage forms are gaining popularity in recent time, as this dosage forms requires no water for administration. Oral films 
dissolve rapidly along with drug in mouth and majority of the drug is absorbed through buccal/oral mucosa in to systemic circulation avoiding 
first pass metabolism. Trazodone Hydrochloride (TRZ), an serotonin reuptake inhibitor antidepressant. TRZ undergoes first pass metabolism 
on oral administration resulting in reduced bioavailability (60%). Thus the objective of the present study was to formulate and evaluate fast 
dissolving oral films of TRZ to overcome the limitation of bioavailability and increase patient’s compliance.  In the present study oral films were 
prepared by solvent casting method using HPMC K15 as a film formers and PEG 400, glycerine as plasticizers and evaluated for mechanical 
properties, disintegration and in vitro dissolution. All formulations showed good mechanical properties and in vitro drug release. The optimized 
(F5) Formulation (HPMC K15, CCS and PEG 400) Exhibited drug release of 92.12% in 15 minutes which was significantly high when  compared 
to other formulation. 
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INTRODUCTION 
Rapidly dissolving or quick dissolving dosage forms have 
acquired great importance in the pharmaceutical industry 
due to their unique properties and advantages1, 2. These 
systems either dissolve or disintegrate within a minute, on 
contact little quantity of water or by chewing. This delivery 
system consists of a thin film, which is simply placed on the 
patient’s tongue or mucosal tissue, instantly wet by saliva; 
the film rapidly dissolves. Then it rapidly disintegrates and 
dissolves to release the medication for oral mucosal 
absorption 3,4. The major portion of the active ingredient is 
swallowed orally along the saliva and absorption takes place 
in the gastrointestinal tract subsequently making them 
particularly suitable for pediatrics and geriatric patients. The 
fast dissolving films were introduced in 1970’s as an 
alternative to the conventional tablet and capsule which 
require swallowing of the dosage form. The rapidly 
dissolving dosage forms are referred by various names by 
researchers like quick disintegrating, orally disintegrating, 
mouth dissolve or melt in mouth dosage forms5,6. These 
dosage forms offer specific advantages including no need of 
water for disintegration, accurate dosing, ease of transport, 
handling, acceptable taste, rapid onset of action and patient 
compliance7. The trans mucosal deliveries of metformin, 
dexamethasone and levocetrizine hydrochloride have proved 
their enhanced bioavailability over the conventional 
formulations8-10. Solvent casting was proved to be reliable 
technique for the manufacturing of fast dissolving films. The 
film strips prepared by this method undergo instantaneous 
disintegration upon placing in buccal/oral cavity. The 
plasticizers present in fast dissolving films formulation, 
reduce the glass transition temperature and thereby 
enabling desired film qualities10. TRZ is chemically 2-{3-[4-
(3-chlorophenyl) piperazin-1-yl] propyl}-2H, 3H-[1, 2, 4] 
triazolo[4,3-a]pyridin-3-one. It is a serotonin antagonist and 
reuptake inhibitor (SARI), which is a second generation 
antidepressant compound belonging to the class of phenyl 
piperazine. It acts as a serotonin agonist at high doses and 
low doses. The drug showing antidepressant activity is due 
to the blockage of serotonin reuptake by inhibiting serotonin 
reuptake pump at the presynaptic neuronal membrane. TRZ 
shows its therapeutic actions through 5-HT2A receptors. TRZ 
also induces anti-anxiety and sleep inducing effects11. It does 
not have similar properties to selective serotonin reuptake 
inhibitors (SSRIs) since its inhibitory effect on serotonin 
reuptake and 5-HT2C receptors are relatively weak12. The 
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result of α-adrenergic action blocking and modest histamine 
blockade at H receptor due to sedative effect of TRZ. It 
weakly blocks presynaptic α2-adrenergic receptors and 
strongly inhibits postsynaptic α1 receptors. TRZ does not 
show any action on the reuptake of norepinephrine or 
dopamine within the CNS. It has fewer anticholinergic side 
effects than most of the tricyclic antidepressants such as dry 
mouth, constipation and tachycardia. TRZ metabolizes to its 
primary m-chlorophenyl piperazine (mCPP) which is a non 
selective serotonin receptor agonist which might outweigh 
the benefits of TRZ13-16. Initial investigations were focused on 
the development of placebo fast dissolving films with good 
peelability, appearance and a quick disintegration time. After 
choosing the components for the placebo film, TRZ loaded 
films were formulated. Although, fast dissolving film is an 
attractive dosage form for the delivery of TRZ. Finally fast 
dissolving films using HPMC and CCS were formulated and 
evaluated. 
MATERIALS AND METHODS 
Trazodone HCl were obtained as pure sample from Sun 
Pharmaceutical Industries Ltd. Dewas, as gift samples along 
with their analytical reports. HPMC K15M, PEG-400, SSG, CCS 
was obtained from Mapromax, Life sciences Pvt. Ltd. 
Dehradun. Aspartame, citric acid was obtained from Loba 
Chemical Pvt Ltd (Mumbai, India). Hydrochloric acid was 
obtained from S. D. Fine Chem. Ltd., Mumbai. All other 
chemical were purchased from Hi Media, Mumbai. Double 
distilled water was prepared freshly and used whenever 
required. All other chemicals used in this study including 
those stated were of analytical reagent (A.R.) grade. 
 
Drug-excipient compatibility study 
FTIR spectra of pure drugs, polymers used, and blends were 
recorded on KBr disk method using Brukers Alpha 
Spectrophotometer with IR solution software to confirm the 
compatibility between drug and excipients. Sample powder 
was thoroughly mixed by triturating with potassium 
bromide in a glass mortar with pestle and compressed into 
disks in a hydraulic press (Techno search Instruments, 
India). FTIR spectra of all the samples were recorded over a 
spectral region from 4700 to 400 cm-1 using 20 scans with 4 
cm-1 resolution. 
Preparation of oral films 
Drug (TRZ) containing fast dissolving films were fabricated 
by the solvent casting method. The optimized amount of 
HPMC was dissolved in 5mL of water and stirrer 
continuously for 1 hour, optimized amount of Plasticizer and 
drug were dissolved in 95 % ethanol and then added to the 
polymeric solution, Polymeric solution was stirred for 30 
min using magnetic stirrer and was kept in undisturbed 
condition till the entrapped air bubbles were removed. The 
aqueous solution was casted in a glass moulds having 2.5 x 
2.5 cm,  10 films area and was dried at controlled room 
temperature (25-30°C, 45 % RH) as well as at increased 
temperature (microwave oven). The film took approximately 
48 hr to dry at controlled room temperature. The dried film 
was carefully removed from the glass plates and was cut into 
size required for testing. The films were stored in air tight 
plastic bags till further use. Formulations were prepared 
using HPMC K15, PEG-400, SSG and CCS at different drug: 
polymer ratios. The compositions of the formulations were 
shown in table 1. 
 
Table 1 Formulation of trazodone hydrochloride oral fast dissolving films 
Name of ingredients 
(mg for 12 strips) 
F1 F2 F3 F4 F5 F6 
TRZ (mg) 600 600 600 600 600 600 
HPMC K15 (mg) 800 100 1200 800 100 1200 
Glycerin (mg) - - - - - - 
PEG-400 (mg) 100 100 100 100 100 100 
SSG (mg) 200 300 400 - - - 
CCS (mg) - - - 200 300 400 
Aspartame (mg) 60 60 60 60 60 60 
Citric acid (mg) 120 120 120 120 120 120 
DM water  qs to (ml) - - - - - - 
 
Evaluation 
The formulations were evaluated by the following tests. 
Thickness 
Randomly 10 films were selected and thickness was 
measured using vernier calliper at three different places. 
Weight variation  
For each formulation, three randomly selected patches were 
used. For weight variation test, 10 films from each batch 
were weighed individually by digital electronic balance and 
the average weight was calculated. 
Drug content analysis 
The patches (n = 3) of specified area were taken into a 10 ml 
volumetric flask and dissolved in methanol and volume was 
made up with 10 ml methanol. Subsequent dilutions were 
made and analyzed by UV spectrophotometer.  
Folding endurance 
This was determined by repeatedly folding one film at the 
same place until it broke. The number of times the film could 
be folded at the same place without breaking cracking gave 
the value of folding endurance.  
Percentage of moisture content 
The films were weighed individually and kept in desiccators 
containing activated silica at room temperature for 24 hrs. 
Individual films were weighed repeatedly until they showed 
a constant weight. The percentage of moisture content was 
calculated as the difference between initial and final weight.  
In vitro dissolution study  
The in vitro dissolution test was performed using the 
USPXXX dissolution apparatus II (Paddle with sinker). The 
dissolution studies were carried out at 37±0.5°C; with 
stirring speed of 50 rpm in 900 ml phosphate buffer (pH 
6.8). Film size required for dose delivery (2.5×2.5 cm2) was 
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used. Five ml aliquot of dissolution media was collected at 
time intervals of 1, 2, 5, 10 and 15 minutes and replaced 
with equal volumes of phosphate buffer (pH 6.8). The 
collected samples were filtered through 0.45 μm membrane 
filter and the concentration of the dissolved TRZ was 
determined using UV-Visible spectrophotometer at 246nm. 
The results were presented as an average of three such 
concentrations. 
Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of one, two and 
three months at 40±2oC temperature and 75±5% relative 
humidity for a period 3 months. The % Assay of formulation 
was determined by U.V. spectrophotometer using calibration 
curve method. The % assay of film was found to slightly 
decrease at higher temperature.  
Physical appearance and texture analysis of the films 
These parameters were checked simply with visual infection 
of films and by feel or touch. 
In vitro disintegration 
The film of (4.15cm2) size (unit dose) was placed on a 
petridish containing 10 ml of distilled water. The time 
required for the film to break was noted as cursive in vitro 
disintegration time. 
Measurement of mechanical properties 
Microprocessor based advanced force gauge tensiometer 
(DS 2 series) equipped with a 50 kg 
load cell was used to determine the mechanical properties of 
OFDFs. Film of 60x10 mm2 was fixed between two clamps 
separated by a distance of 3 cm17. The lower clamp was held 
stationary and the strips were pulled apart by the upper 
clamp moving at a rate of 2 mm/sec until the strip broke. 
The force and elongation of the film at the point when the 
strip broke was recorded. The tensile strength and percent 
elongation values were calculated using the following 
formula. 
Tensile strength = load at breakage/film thickness × film 
width 
% Elongation = increase in length ×100/original length 
RESULTS AND DISCUSSION 
Solubility of TRZ was freely soluble in methanol and ethanol, 
slightly soluble in 0.1N NaOH, soluble in water, 0.1N HCL and 
6.8 pH phosphate buffers. The melting point of TRZ was 223-
226ºC and λ max of TRZ was found to be 246.0 nm by using 
U.V. spectrophotometer (Labindia-3000+). The general 
appearance, assay, weight variation and thickness of all the 
films were within acceptable limits table 2. The results for 
tensile strength, folding endurance, disintegrating time, % 
elongation and % of moisture were shown in table 3. Tensile 
strength value of optimized formulation (F5) was 
1.224±0.065 kg/cm2 and percent elongation 6.67±0.62. The 
folding endurance of the optimized oral fast dissolving 
formulation (F5) was 122.35±6.45. The formulations 
containing CCS were showing good results compared to SSG. 
The assay values of all the formulations were ranging from 
92.25 to 98.89 %. The disintegration time was ranging 
between 52 to more than 92 sec. The final formulation 
shows better drug release (92.12%) compared to other 
formulation within 15 m (Figure 1). The cumulative 
percentage (%) drug release profile and the assay of the F5 
formulation films indicates that the drug remain stable 
under the ASC without any significant change in its release 
profile and the drug content. From the stability studies it 
was clearly observed that the drug showed good stability 
after subjecting to accelerated stress conditions and the 
polymers shown significantly compatibility with the drug. 
 
Table 2 Result of thickness and weight variation 
F. code General 
Appearance 
Thickness in µm Weight(mg) Mean 
± S.D 
% Assay 
F1 Translucent 90±2 158±4 92.25±0.14 
F2 Translucent 93±5 155±3 95.45±0.28 
F3 Translucent 89±5 160±1 94.65±0.36 
F4 Translucent 93±6 162±2 95.65±0.24 
F5 Translucent 95±4 159±5 98.89±0.14 
F6 Translucent 94±2 160±4 97.45±0.16 
 
Table 3 Result of folding endurance, disintegrating time, tensile strength, % elongation &% of moisture content 
F. 
code 
Folding 
endurance 
(Times) 
Disintegrating 
time (Sec) 
Tensile 
strength  in  
kg/cm2 
% 
elongation 
Mean ± S.D 
% of moisture 
content 
F1 103.33 ± 9.87 92±4 0.620±0.056 5.94 ± 0.88 0.698±0.111 
F2 105.25 ± 4.56 80±6 0.680±0.045 4.29 ± 0.67 0.647±0.101 
F3 99.33 ± 7.67 75±7 1.212±0.012 2.24 ± 0.57 0.897±0.142 
F4 111.02 ± 8.55 60±6 1.542±0.045 4.35 ± 0.66 0.998±0.156 
F5 122.35 ± 6.45 52±4 1.224±0.065 6.67 ± 0.62 0.898±0.136 
F6 120.66 ± 5.29 55±5 1.269±0.045 3.21 ± 0.21 0.956±0.145 
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Figure 1 Graph of In vitro drug release study of optimized formulation 
CONCLUSION 
From present investigation it can be concluded that oral fast 
dissolving films are superior in drug release. The films 
prepared by HPMC and PEG 400 had shown good mechanical 
strength, drug release, disintegration time and stability. F5 
formulation is considered as the best according to the 
obtained results with less disintegrating time and complete 
drug release in 15 min. Percent drug release and 
disintegration time was taken as responses for study which 
were found within the accepted ranges. As the concentration 
of CCS was increased, both the disintegration and the drug 
release rates increased. The disintegration and release rates 
were found to be faster for films prepared with lowest 
concentration of HPMC along with maximum concentration 
of superdisintegrants. TRZ administered in the form of fast 
dissolving films will be potential novel drug dosage form for 
pediatric, geriatric and also for general population by 
providing faster release and better patient compliance. 
REFERENCES 
1. Liang AC, Chen LH. Fast‑dissolving intraoral drug delivery 
systems. Exp Opin Ther Patents 2001; 11:981-6. 
2. Borsadia S, O’Halloran D, Osborne JL. Quick dissolving films‑A 
novel approach to drug delivery. Drug Deliv Technol 2003; 
3:63‑6. 
3. Dixit RP, Puthli SP. Oral strip technology: Overview and future 
potential, J Cont Rel 139; 94-107: 2009.  
4. Vollmer U, Galfetti P. Rapid film: Oral thin films as an 
innovative drug delivery system and dosage form, Drug Dev 
Report 2006; 64-67. 
5. Klancke J. Dissolution testing of orally disintegrating tablets. 
Dissolut Technol 2003; 10:6-8. 
6. Parakh SR, Gothoskar AV. Review of mouth dissolving 
tablettechnologies. Pharm Tech 2003; 27:92–100. 
7. Kunte S, Tandale P. Fast dissolving strips: a novel approach for 
the delivery of verapamil, J Pharm Bioallied Sci 2010; 2(4); 
325-328. 
8. Sushma M, Prasanna YR, Sundaresan C, Vandana K, Kumar NV, 
Chowdary VH. Transmucosal delivery of metformin- A 
comprehensive study, Curr Drug Deliv July 2013. PMID: 
23848354. 
9. Shimoda H, Taniguchi K, Nishimura M, Matsuura K, Tsukioka 
T, Yamashita H, et al. Preparation of a fast dissolving oral thin 
film containing dexamethasone: a possible application to anti-
emesis during cancer chemotherapy, Eur J Pharm 
Biopharm2009; 73(3): 361-365.  
10. Prabhu P, Malli R, Koland M, Vijaynarayana K, D'Souza U, 
Harish N et al. Formulation and evaluation of fast dissolving 
films of levocitirizine dihydrochloride. Int J Pharm Inv 2011; 
1(2): 99-104. 
11. Haria M, Fitton A, McTavish D. Trazodone. A review of its 
pharmacology, therapeutic use in depression and therapeutic 
potential in other disorders. Drugs Aging 1994; 4: 331-355. 
12. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of 
trazodone and fluoxetine: implications for a serotonergic 
mechanism of antidepressant action. Psychopharmacology 
(Berl) 1992; 109: 2-11. 
13. Fong MH, Garattini S, Caccia S. 1-m-Chlorophenylpiperazine is 
an active metabolite common to the psychotropic drugs 
trazodone, etoperidone and mepiprazole. J Pharm Pharmacol 
1982; 34: 674-675. 
14. Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters 
A, et al. Effects of trazodone and fluoxetine in the treatment of 
major depression: therapeutic pharmacokinetic and 
pharmacodynamic interactions through formation of meta-
chlorophenylpiperazine. J Clin Psychopharmacol 1997; 17: 
358-364. 
15. Kast RE. Trazodone generates m-CPP: in 2008 risks from m-
CPP might outweigh benefits of trazodone. World J Biol 
Psychiatry 2009; 10: 682-685. 
16. Mihara K, Yasui-Furukori N, Kondo T, Ishida M, Ono S et al. 
Relationship between plasma concentrations of trazodone and 
its active metabolite, m-chlorophenylpiperazine and its 
clinical effect in depressed patients. Ther Drug Monit 2002; 
24: 563-6. 
17. Himabindu S, Sathish D, Shayeda. Formulation and in-vitro 
evaluation of mucoadhesive buccal patches of cyproheptadine 
hydrochloride. J Appl Pharm Sci 2012; 2: 196-201. 
 
 
